“…Since the discovery of NAB2/STAT6's role in SFT tumorigenesis [5][6][7] and the subsequent advent of STAT6 immunohistochemical marker, SFTs are more easily Table 2 Previously performed IHC results for 24 cases of MF; Cases 1-20 have been published prior in the literature [14] MF Previous IHC 1 αSMA+, desmin-, S100-, focal calponin+ 2 αSMA+, desmin-, vimentin+, CD34-, S100-3 αSMA+, desmin-, vimentin +, S100-4 αSMA+, MSA+, desmin-, S100-, CD34-5 αSMA+, MSA+, desmin-, vimentin +, S100-6 αSMA+, desmin-,S100-7 αSMA+, desmin-,S100-8 αSMA+, desmin-,S100-, CD34-9 αSMA+, MSA+, desmin-, H-caldesmon-, S100-10 αSMA+, MSA+, desmin-, vimentin+, AE1/3-, S100-11 αSMA+, desmin-,CD68-, AE1/3-, Cam 5.2-, S100-12 αSMA+, MSA+, desmin-, vimentin +, S100-13 αSMA+, desmin-,S100-, CD34-14 αSMA+, desmin-,S100-, CD68-15 αSMA+, MSA-, desmin-, S100-16 αSMA+, desmin-, CD34-, S100-, CD68-17 αSMA+, desmin-, CD34-, CD68-18 αSMA+, MSA+, desmin-, vimentin +, S100-, Factor 8-, CD68-19 αSMA+, desmin-,S100-, CD34-20 αSMA+, MSA+, desmin-,vimentin+ 21 αSMA+, MSA+, desmin-, CD68-, CD34-, S100-22 αSMA+, desmin-, S100-, CD68-23 αSMA+, desmin-, S100-24 αSMA+, S100- differentiated from other soft tissue tumors. While multiple researchers have reported the sensitivity and specificity of STAT6 expression in SFTs and its histopathologic mimickers [8][9][10][11][12][13], we were only able to find information about its expressivity in MFs for five cases in the literature: one case in a large series by Demicco et al (which reported negative STAT6 expressivity) [8] and four cases in a study by Yoshida et al [13].…”